Drugs / Frozen Plasma Product, Human
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05523297 Comparator | Nov 2022 → Jun 2024 | — | Octapharma | Completed | Met primary |
| Phase 3 | NCT03341156 Comparator | Jul 2018 → Sep 2020 | advanced heart failure, congestive heart failure | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Frozen Plasma Product, Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05523297 ↗ |
| Known as | frozen plasma | “Patients were randomized to receive either 4-factor PCC (Octaplex) or frozen plasma (FP).” NCT05523297 ↗ |
| Modality | Protein / enzyme biologic | “frozen plasma (FP) is the standard haemostatic therapy after cardiopulmonary bypass” PMID 42404094 ↗ Jun 2026 |
| Route | Intravenous | “fresh frozen plasma intravenously before cardiopulmonary bypass” NCT03341156 ↗ |